Bilal Abou Ali1,2, Nader Hirmas2, Hani Tamim3, Zeina Merabi1, Rima Hanna-Wakim2, Samar Muwakkit1,2, Miguel Abboud1,2, Hassan El Solh1,2, Raya Saab1,2. 1. Children's Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon. 2. Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon. 3. Department of Internal Medicine, Clinical Research Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Abstract
BACKGROUND: Pediatric oncology patients with fever, even when not neutropenic, are known to be at an increased risk of bloodstream infections. However, there are no standard guidelines for management of fever in non-neutropenic patients, resulting in variability in practice across institutions. PROCEDURE: We retrospectively analyzed the clinical characteristics, management, and outcome of all febrile non-neutropenic episodes in pediatric oncology patients at a single institution over the two-year period 2011-2012, to identify predictors of bloodstream infections. We assessed the efficacy of a uniform approach to outpatient management of a defined subset of patients at low risk of invasive infections. RESULTS: A total of 254 episodes in 83 patients were identified. All patients had implanted central venous catheters (port). Sixty-two episodes (24%) were triaged as high-risk and admitted for inpatient management; five (8%) had positive blood cultures. The remaining 192 episodes were triaged as low risk and managed with once daily outpatient intravenous ceftriaxone; three (1.6%) were associated with bacteremia, and 10% required eventual inpatient management. Of all the factors analyzed, only signs of sepsis (lethargy, chills, hypotension) were associated with positive bloodstream infection. CONCLUSIONS: Treatment of a defined subset of patients with outpatient intravenous ceftriaxone was safe and effective. Signs of sepsis were the only factor significantly associated with bloodstream infection. This study provides a baseline for future prospective studies assessing the safety of withholding antibiotics in this subset of patients.
BACKGROUND: Pediatric oncology patients with fever, even when not neutropenic, are known to be at an increased risk of bloodstream infections. However, there are no standard guidelines for management of fever in non-neutropenicpatients, resulting in variability in practice across institutions. PROCEDURE: We retrospectively analyzed the clinical characteristics, management, and outcome of all febrile non-neutropenic episodes in pediatric oncology patients at a single institution over the two-year period 2011-2012, to identify predictors of bloodstream infections. We assessed the efficacy of a uniform approach to outpatient management of a defined subset of patients at low risk of invasive infections. RESULTS: A total of 254 episodes in 83 patients were identified. All patients had implanted central venous catheters (port). Sixty-two episodes (24%) were triaged as high-risk and admitted for inpatient management; five (8%) had positive blood cultures. The remaining 192 episodes were triaged as low risk and managed with once daily outpatient intravenous ceftriaxone; three (1.6%) were associated with bacteremia, and 10% required eventual inpatient management. Of all the factors analyzed, only signs of sepsis (lethargy, chills, hypotension) were associated with positive bloodstream infection. CONCLUSIONS: Treatment of a defined subset of patients with outpatient intravenous ceftriaxone was safe and effective. Signs of sepsis were the only factor significantly associated with bloodstream infection. This study provides a baseline for future prospective studies assessing the safety of withholding antibiotics in this subset of patients.
Authors: Adam J Esbenshade; Zhiguo Zhao; Catherine Aftandilian; Raya Saab; Rachel L Wattier; Melissa Beauchemin; Tamara P Miller; Jennifer J Wilkes; Michael J Kelly; Alison Fernbach; Michael Jeng; Cindy L Schwartz; Christopher C Dvorak; Yu Shyr; Karl G M Moons; Maria-Luisa Sulis; Debra L Friedman Journal: Cancer Date: 2017-05-23 Impact factor: 6.860
Authors: José Antonio Villegas Rubio; Pilar Palomo Moraleda; Ana De Lucio Delgado; Gonzalo Solís Sánchez; Belén Prieto García; Corsino Rey Galán Journal: Children (Basel) Date: 2022-06-03
Authors: Stefan Schöning; Anke Barnbrock; Konrad Bochennek; Kathrin Gordon; Andreas H Groll; Thomas Lehrnbecher Journal: Antibiotics (Basel) Date: 2022-07-05